Your browser doesn't support javascript.
loading
A survey study of Alzheimer's stigma among Black adults: intersectionality of Black identity and biomarker diagnosis.
Stites, Shana D; Midgett, Sharnita; Largent, Emily A; Harkins, Kristin; Schumann, Rosalie; Sankar, Pamela; Krieger, Abba.
Affiliation
  • Stites SD; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Midgett S; Division of Geriatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Largent EA; Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Harkins K; Division of Geriatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Schumann R; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Sankar P; Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Krieger A; Department of Statistics, Wharton School of Business, University of Pennsylvania, Philadelphia, PA, USA.
Ethn Health ; : 1-17, 2024 Jul 30.
Article in En | MEDLINE | ID: mdl-39079935
ABSTRACT

OBJECTIVE:

We urgently need to understand Alzheimer's disease (AD) stigma among Black adults. Black communities bear a disproportionate burden of AD, and recent advances in early diagnosis using AD biomarkers may affect stigma associated with AD. The goal of our study is to characterize AD stigma within our cohort of self-identified Black participants and test how AD biomarker test results may affect this stigma.

DESIGN:

We surveyed a sample of 1,150 self-identified Black adults who were randomized to read a vignette describing a fictional person, who was described as either having a positive or negative biomarker test result. After reading the vignette, participants completed the modified Family Stigma in Alzheimer's Disease Scale (FS-ADS). We compared FS-ADS scores between groups defined by age, gender, and United States Census region. We examined interactions between these groupings and AD biomarker test result.

RESULTS:

Participants over age 65 had lower scores (lower stigma) on all 7 FS-ADS domains compared to those under 65 structural discrimination, negative severity attributions, negative aesthetic attributions, antipathy, support, pity, and social distance. In the biomarker positive condition, worries about structural discrimination were greater than in the biomarker negative condition and statistically similar in the two age groups (DOR, 0.39 [95%CI, 0.22-0.69]). This pattern of results was similar for negative symptom attributions (DOR, 0.51 [95%CI, 0.28-0.90]).

CONCLUSION:

While older adults reported less AD stigma than younger adults, AD biomarker testing caused similarly high concerns about structural discrimination and negative severity attributions. Thus, use of AD biomarker diagnosis may increase AD stigma and exacerbate healthcare disparities known to effect AD diagnosis in some Black adults. Advances in AD diagnosis may interact with social and structural factors to differentially affect groups of Black adults.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ethn Health / Ethn. health / Ethnicity & health Journal subject: CIENCIAS SOCIAIS / SAUDE PUBLICA Year: 2024 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ethn Health / Ethn. health / Ethnicity & health Journal subject: CIENCIAS SOCIAIS / SAUDE PUBLICA Year: 2024 Document type: Article Affiliation country: United States Country of publication: United kingdom